Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population

Conclusions: Long-term AL survivors have distinct favorable baseline characteristics (including those introduced by referral bias) and ASCT as their initial therapy. Identification of these patients, especially the Mayo 2004 stage III and the Mayo 2012 stage III-IV patients who unexpectedly survived 10 years, will allow for further study and insights.DisclosuresGertz: Teva: Consultancy; Prothena: Honoraria; Alnylam: Honoraria; celgene: Consultancy; Ionis: Honoraria; Physicians Education Resource: Consultancy; Research to Practice: Consultancy; Amgen: Consultancy; janssen: Consultancy; Apellis: Consultancy; Medscape: Consultancy; Abbvie: Consultancy; spectrum: Consultancy, Honoraria; annexon: Consultancy. Lacy: Celgene: Research Funding. Dingli: Alexion Pharmaceuticals, Inc.: Other: Participates in the International PNH Registry (for Mayo Clinic, Rochester) for Alexion Pharmaceuticals, Inc.; Millennium Takeda: Research Funding; Millennium Takeda: Research Funding; Alexion Pharmaceuticals, Inc.: Other: Participates in the International PNH Registry (for Mayo Clinic, Rochester) for Alexion Pharmaceuticals, Inc.. Kapoor: Takeda: Research Funding; Celgene: Research Funding. Russell: Vyriad: Equity Ownership. Kumar: KITE: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Janssen: Membership on an entity's Board of Directors...

Source: Blood - November 21, 2018 Category: Hematology Authors: Muchtar, E., Gertz, M. A., Lacy, M. Q., Dingli, D., Buadi, F. K., Grogan, M., abou Ezzeddine, O. F., Hayman, S. R., Kapoor, P., Leung, N., Fonder, A., Hobbs, M., Hwa, Y., Gonsalves, W. I., Warsame, R., Kourelis, T., Russell, S. J., Lust, J. A., Lin, Y., G Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster II Source Type: research